
Please try another search
For the three months ended 31 March 2022, AnaptysBio Inc revenues decreased 91% to $970K. Net loss increased 100% to $36.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Stock-based Compensation in General and increase from $2.1M to $6.1M (expense), General and administrative - Balancing increase of 25% to $4.1M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0.97 | 1.01 | 20.89 | 30.03 |
Gross Profit | ||||
Operating Income | -31.75 | -31.16 | -6.76 | -0.53 |
Net Income | -36.26 | -32.54 | -6.67 | -0.43 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 625.17 | 643.07 | 424.33 | 426.57 |
Total Liabilities | 294.42 | 286.64 | 40.73 | 40.84 |
Total Equity | 330.75 | 356.43 | 383.61 | 385.73 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -21.01 | -45.92 | -20.62 | -13.61 |
Cash From Investing Activities | -312.91 | 38.84 | 105.53 | 94.69 |
Cash From Financing Activities | 4.61 | 252.3 | 0.96 | 0.72 |
Net Change in Cash | -329.32 | 245.21 | 85.87 | 81.8 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review